Solo-Dex Inc. has announced a national distribution agreement for its proprietary continuous peripheral nerve block catheters with InfuSystem Holdings Inc., a national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, based in Rochester Hills, Michigan.
With Solo-Dex catheter over the needle technology, all anesthesiologists can place facile continuous peripheral block catheter in two to three minutes for common procedures such as shoulder repair, hip and knee replacement as well as general surgical procedures. Once placed, Solo-Dex products are designed to remain in place introducing the type, quantity and volume of acute pain management medication continuously for days.
Continuous regional anesthesia coupled with mild sedation may eliminate the need for a patient to receive general anesthesia which requires the manipulation of the airway, may disrupt the patient’s cognition and extends recovery. For the surgical team, manipulation of the airway may increase the risk of COVID-19 exposure for the surgical team.
Safe and effective acute pain management can be delivered via continuous peripheral nerve block, days before, during and after surgery. The patient tends to recover more quickly and may be released for home recovery with a block that eliminates the need for oral opioid painkillers.
“Solo-Dex Facile, coupled with InfuSystem’s InfuBLOCK Pain Management Therapy program and follow-up services, are now collaborating to bring cost-effective, easy-to-use continuous regional acute pain management to a market which is estimated to be 10 times larger than the current nerve catheter market,” remarked Steven Eror, CEO of Solo-Dex, “the stage is set for the emergence of a new standard of care.”
“InfuSystem is pleased to join with Solo-Dex in bringing innovation to the acute pain management market. Solo-Dex will bring technology to our customers that makes it easier for the anesthesiologist to place nerve block catheters safely and effectively. As a result, we believe more patients will have the opportunity to receive our services and recover quickly without requiring the use of oral opioid pain management,” said Richard DiIorio, chief executive officer of InfuSystem.
For more information, visit Solo-Dex.com or infusystem.com.
